Oxford Technology & Innovations EIS Fund (OTIF) subscribes to Caristo Diagnostics’ £13m Series A raise.

Oxford Investment Consultants LLP (OIC) is pleased to announce that the Oxford Technology & Innovations EIS Fund (OTIF) has subscribed to Caristo Diagnostics’ £13m Series A raise.

Cardiovascular diseases are the leading causes of death, with coronary artery disease (CAD) and Stroke accounting for 27% of deaths worldwide. Atherosclerosis, the build-up of plaques in artery walls, is the primary cause of heart attacks and stroke.

Caristo’s founding team discovered and patented the Fat Attenuation Index (FAI), a groundbreaking new biomarker that measures inflammation surrounding the coronary arteries, a driver of the disease process of atherosclerosis and rupture of plaques. The CaRi-Heart® analysis combines FAI-Score with a patient’s clinical risk factors and plaque burden within a simple report that provides a comprehensive assessment of an individual’s risk of a fatal heart attack.

Frank Cheng, Caristo CEO, said: “Caristo has been on an exciting journey since 2018 as the Company turned a scientific idea into a validated clinical offering, protected our intellectual property, published impressive results in leading peer-reviewed medical journals, and secured initial regulatory approvals. Our Series A fundraise will accelerate Caristo’s growth in our existing UK and EU markets, while we lay solid foundations for U.S. market entry”.

Heather Roxborough, Head of HealthTech at Oxford Science Enterprises, said: “We invest in companies with the potential to revolutionise healthcare and become global category leaders and that is why we are proud to back the incredible team at Caristo. Caristo continues to make tremendous progress in the delivery of its innovative technology to help healthcare professionals predict and prevent future heart attacks and ultimately save millions of lives around the world. We are thrilled to continue being part of the company’s journey.”

Read the full article here.